Lomitapide (Juxtapid®)


Indications for Prior Authorization:

  • Treatment of adult patients homozygous familial hypercholesterolemia (HoFH)

Patients must meet the following criteria for the indication(s) above:

  • Patient is on low fat diet and other lipid lowering medications with inadequate response
  • All patients must undergo genetic testing to confirm HoFH status

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:

  • All non-FDA approved uses not listed in the approved indications


  • Initial dose 5 mg orally once a day
  • Increase to 10 mg daily after at least two weeks based on tolerability
  • At four week intervals increase to 20 mg, 40mg, 60 mg (maximum dose) daily if necessary based on efficacy and tolerability


One year

Box warnings for:

  • Hepatotoxicity


Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.